The abstract is read at the publisher; the summary is JClub's.
Nanobodies generated by yeast display bind the MR1-5-OP-RU complex with high affinity, cobinding MR1 and 5-OP-RU like a TCRm antibody.
- Why it matters: It was unclear whether antibodies could be made to specifically target MR1 presenting conserved microbial metabolites such as 5-OP-RU, a key step for MR1-directed T cell therapies.
- What they did: The authors used yeast display to isolate high-affinity nanobodies against MR1-5-OP-RU, then tested binding to mouse and human MR1-5-OP-RU and assessed MAIT inhibition and bioactivity in vitro and in vivo.
- The result: Lead nanobody crystal structures showed cobinding of MR1 and 5-OP-RU, and engineered MR1-5-OP-RU/CD3 bispecific antibodies redirected immunity to kill bacterially infected cells and 5-OP-RU–treated tumor cells.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.